Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.725 USD | +1.21% | +0.69% | -11.77% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Business Summary
Number of employees: 9
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 20-02-29 |
Chief Operating Officer | - | 20-09-30 | |
Steven J. Ruhl
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 23-01-09 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 20-05-31 |
Director/Board Member | 65 | 22-05-11 | |
Barbara Finck
BRD | Director/Board Member | 77 | 22-03-15 |
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Donald Williams
BRD | Director/Board Member | 65 | 20-05-31 |
Scott Brun
BRD | Director/Board Member | 56 | 22-11-09 |
Director/Board Member | 66 | 20-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,394,882 | 29,153,718 ( 80.10 %) | 0 | 80.10 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.77% | 26.07M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- FBRX Stock
- Company Forte Biosciences, Inc.